These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26530361)

  • 1. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
    Beckman RA; Chen C
    Adv Exp Med Biol; 2015; 867():81-90. PubMed ID: 26530361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs.
    Beckman RA; Chen C
    Chin J Cancer; 2013 May; 32(5):233-41. PubMed ID: 23489587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating predictive biomarkers within oncology clinical development programs.
    Beckman RA; Chen C
    Biomark Med; 2015; 9(9):851-62. PubMed ID: 26330133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives.
    Mordente A; Meucci E; Martorana GE; Silvestrini A
    Adv Exp Med Biol; 2015; 867():9-26. PubMed ID: 26530357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
    Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
    Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
    Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating predictive biomarkers and classifiers into oncology clinical development programmes.
    Beckman RA; Clark J; Chen C
    Nat Rev Drug Discov; 2011 Sep; 10(10):735-48. PubMed ID: 21959287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker analysis for oncology.
    Ma Y; Gamagedara S
    Biomark Med; 2015; 9(9):845-50. PubMed ID: 26330199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New directions in biomarker research, drug development and personalized medicine].
    Németh G; Jelinek I
    Magy Onkol; 2013 Mar; 57(1):5-10. PubMed ID: 23573515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Very) Early technology assessment and translation of predictive biomarkers in breast cancer.
    Miquel-Cases A; Schouten PC; Steuten LM; Retèl VP; Linn SC; van Harten WH
    Cancer Treat Rev; 2017 Jan; 52():117-127. PubMed ID: 27992844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies.
    Umelo IA; Costanza B; Castronovo V
    Cancer Metastasis Rev; 2018 Mar; 37(1):125-145. PubMed ID: 29392535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The breakthrough of personalized medicine, new hopes and new challenges].
    Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
    Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-Oncology in the Era of Personalized Medicine.
    Gwin WR; Disis ML; Ruiz-Garcia E
    Adv Exp Med Biol; 2019; 1168():117-129. PubMed ID: 31713168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Biomarkers on Personalized Medicine.
    Carrigan P; Krahn T
    Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers.
    Saumet A; Lecellier CH
    Adv Exp Med Biol; 2015; 888():5-15. PubMed ID: 26663176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
    Jones RT; Felsenstein KM; Theodorescu D
    Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project.
    Niklinski J; Kretowski A; Moniuszko M; Reszec J; Michalska-Falkowska A; Niemira M; Ciborowski M; Charkiewicz R; Jurgilewicz D; Kozlowski M; Ramlau R; Piwkowski C; Kwasniewski M; Kaczmarek M; Ciereszko A; Wasniewski T; Mroz R; Naumnik W; Sierko E; Paczkowska M; Kisluk J; Sulewska A; Cybulski A; Mariak Z; Kedra B; Szamatowicz J; Kurzawa P; Minarowski L; Charkiewicz AE; Mroczko B; Malyszko J; Manegold C; Pilz L; Allgayer H; Abba ML; Juhl H; Koch F;
    Adv Med Sci; 2017 Sep; 62(2):405-413. PubMed ID: 28646744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.